Penetration of efavirenz into the male genital tract: drug concentrations and antiviral activity in semen and blood of HIV-1-infected men
- 1 October 2001
- journal article
- research article
- Published by Wolters Kluwer Health in AIDS
- Vol. 15 (15) , 2051-2053
- https://doi.org/10.1097/00002030-200110190-00022
Abstract
Efavirenz is a potent non-nucleoside reverse transcriptase inhibitor, licensed for the treatment of HIV-1. Data on sanctuary site penetration are limited. Therefore, we measured efavirenz concentrations in the blood and semen of 19 HIV-1-positive men and found concentrations in seminal plasma averaged 10% of those in blood plasma. Furthermore, seminal plasma viral loads were suppressed by 24 weeks of therapy in all patients. These data suggest that efavirenz-containing regimens have antiviral activity within the male genital tract.Keywords
This publication has 3 references indexed in Scilit:
- Antiretroviral drug concentrations in semen of HIV-1 infected menSexually Transmitted Infections, 2001
- Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patientsAIDS, 2001
- Concentrations of nevirapine, lamivudine and stavudine in semen of HIV-1-infected menAIDS, 2000